943 related articles for article (PubMed ID: 21177428)
1. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
3. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
6. Roles for lysophospholipid S1P receptors in multiple sclerosis.
Noguchi K; Chun J
Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
[TBL] [Abstract][Full Text] [Related]
7. FTY720 requires vitamin B
Jonnalagadda D; Kihara Y; Groves A; Ray M; Saha A; Ellington C; Lee-Okada HC; Furihata T; Yokomizo T; Quadros EV; Rivera R; Chun J
Cell Rep; 2023 Dec; 42(12):113545. PubMed ID: 38064339
[TBL] [Abstract][Full Text] [Related]
8. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
9. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
10. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
12. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
13. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T
PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187
[TBL] [Abstract][Full Text] [Related]
14. Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.
Sheridan GK; Dev KK
Sci Rep; 2014 May; 4():5051. PubMed ID: 24851861
[TBL] [Abstract][Full Text] [Related]
15. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A
Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045
[TBL] [Abstract][Full Text] [Related]
16. S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
Gonzalez-Cabrera PJ; Cahalan SM; Nguyen N; Sarkisyan G; Leaf NB; Cameron MD; Kago T; Rosen H
Mol Pharmacol; 2012 Feb; 81(2):166-74. PubMed ID: 22031473
[TBL] [Abstract][Full Text] [Related]
17. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
18. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
20. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.
Kim HJ; Miron VE; Dukala D; Proia RL; Ludwin SK; Traka M; Antel JP; Soliven B
FASEB J; 2011 May; 25(5):1509-18. PubMed ID: 21248243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
